ASN-90 is under clinical development by Asceneuron and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success ...
Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson'sdisease, and the benefits can be seen in multiple ways, a new study ... Nov. 19, 2024 — A recently published study ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
One such debilitating and devastating condition is called Parkinson’s disease - a degenerative disorder that affects the brain and the central nervous system. Often this condition affects the ...